Bevacizumab
- PMID: 15962523
- DOI: 10.1038/nrd1727
Bevacizumab
Abstract
Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target tumour angiogenesis.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical